[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-348992-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-348992-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","effectiveness-of-neoadjuvant-chemotherapy-lenvatinib-plus-pembrolizumab-in-advanced-endometrial-cancer-a-case-report","Effectiveness of Neoadjuvant Chemotherapy - Lenvatinib plus Pembrolizumab in Advanced Endometrial Cancer: a Case Report","","Combination lenvatinib plus pembrolizumab is an insurance-covered option in Japan for unresectable advanced or recurrent endometrial cancer after platinum-based chemotherapy, but its role as neoadjuvant chemotherapy for unresectable advanced disease remains unclear. This case report describes a 51-year-old Japanese woman with stage IVB (T3aN2M1) endometrial cancer receiving paclitaxel plus carboplatin followed by five cycles of lenvatinib plus pembrolizumab after hemostatic management, leading to tumor shrinkage, surgical resection, and a pathological complete response.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/effectiveness-of-neoadjuvant-chemotherapy-lenvatinib-plus-pembrolizumab-in-advanced-endometrial-cancer-a-case-report/348992/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/effectiveness-of-neoadjuvant-chemotherapy-lenvatinib-plus-pembrolizumab-in-advanced-endometrial-cancer-a-case-report/348992.png","ImageObject",300,407,{"name":42,"@type":43},"Alex Sinclair","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":22},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"Why was neoadjuvant chemotherapy considered for this patient?","Question",{"text":62,"@type":63},"Surgery was considered difficult due to the diagnosis of stage IVB advanced endometrial cancer, so neoadjuvant chemotherapy was used to enable later resection.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"What complications occurred during initial treatment?",{"text":67,"@type":63},"The patient developed massive genital bleeding during treatment, requiring uterine artery embolization and blood transfusion to continue systemic therapy.",{"name":69,"@type":60,"acceptedAnswer":70},"What was the outcome after lenvatinib plus pembrolizumab?",{"text":71,"@type":63},"After five cycles, the tumor markedly shrank, surgery became possible, and the removed uterus showed no residual cancer, consistent with a pathological complete response.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},348992,1790182215,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":22,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":101,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Konnai etal. Journal of Medical Case Reports (2026) 20:172  \n[https://doi.org/10.1186/s13256-026-05920-4](https://doi.org/10.1186/s13256-026-05920-4)  \nJournal of Medical Case Reports  \n CASE REPORT Open Access  \nEffectiveness of neoadjuvant chemotherapy   with lenvatinib plus pembrolizumabin advanced endometrial cancer: a case report  \nKatsuyuki Konnai 1* , Hiroyuki Fujiwara2, Tsuguto Notomi3, Chiaki Yoshikawa1, Tomomi Yokozawa1 and Haruya Saji1  \nAbstract  \nBackground A combination of lenvatinib and pembrolizumab is a viable treatment option for unresectable advanced endometrial cancer after platinum-based chemotherapy; however, its efficacy as neoadjuvant chemotherapy remains to be elucidated.  \nCase presentation The patient was a 51-year-old Japanese woman with severe anemia and suspected endometrial cancer based on magnetic resonance imaging. Adenocarcinoma was detected in the endometrium and diagnosed as stage IVB (T3aN2M1) endometrial cancer. Hysterectomy was considered difficult; therefore, paclitaxel plus carboplatin was administered as neoadjuvant chemotherapy. During treatment, the patient experienced massive genital bleeding, which necessitated uterine artery embolization and blood transfusion. Following these interventions, the bleeding was drastically reduced, enabling the administration of five cycles of lenvatinib plus pembrolizumab. The tumor markedly shrank, allowing surgery to be performed. The removed uterus exhibited induration but no residual cancer.  \nConclusion Lenvatinib plus pembrolizumab may represent a feasible neoadjuvant option for achieving tumor regression and enabling surgical resection with a pathological complete response in advanced endometrial cancer. Keywords Advanced endometrial cancer, Case report, Lenvatinib plus pembrolizumab, Neoadjuvant chemotherapy, Pathological complete response  \nBackground  \nIn Japan, the combination of lenvatinib, a selective multikinase inhibitor, and pembrolizumab, an anti-PD-1 monoclonal antibody, has been covered by health insurance  \n*Correspondence: Katsuyuki Konnai [katujpn@yahoo.co.jp](katujpn@yahoo.co.jp)  \n1 Department of Gynecology, Kanagawa Cancer Center, 2-3-2, Nakao, Asahi-Ku, Yokohama, Kanagawa 241-8515, Japan  \n2 Department of Obstetrics and Gynecology, Jichi Medical University, Tochigi, Japan  \n3 Department of Obstetrics and Gynecology, Nippon Medical School Tama Nagayama Hospital, Tokyo, Japan  \nand is available for patients (since December 2021) with unresectable advanced or recurrent endometrial cancer that has progressed after chemotherapy. Guidelines recommend the combination of paclitaxel plus carboplatin (TC) or doxorubicin plus cisplatin for the treatment of advanced endometrial cancer [1]. Furthermore, lenvatinib plus pembrolizumab is an option for unresectable advanced endometrial cancer after treatment with platinum-based regimens. These recommendations are based on the results of the KEYNOTE-775/309 study [2]. The study investigated the efficacy and safety in patients with incurable endometrial cancer who have received one or two regimens of platinum-based chemotherapy; however, the efficacy of neoadjuvant chemotherapy (NAC) remains  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use ","cbCaip7MalYCY2cn","https://ap.wps.com/l/cbCaip7MalYCY2cn","pdf",2789660,"English","# Abstract\n## Background\n## Case presentation\n## Conclusion\n# Background\n# Case presentation","[{\"question\":\"Why was neoadjuvant chemotherapy considered for this patient?\",\"answer\":\"Surgery was considered difficult due to the diagnosis of stage IVB advanced endometrial cancer, so neoadjuvant chemotherapy was used to enable later resection.\"},{\"question\":\"What complications occurred during initial treatment?\",\"answer\":\"The patient developed massive genital bleeding during treatment, requiring uterine artery embolization and blood transfusion to continue systemic therapy.\"},{\"question\":\"What was the outcome after lenvatinib plus pembrolizumab?\",\"answer\":\"After five cycles, the tumor markedly shrank, surgery became possible, and the removed uterus showed no residual cancer, consistent with a pathological complete response.\"}]","Effectiveness of Neoadjuvant Chemotherapy - Lenvatinib plus Pembrolizumab in Advanced Endometrial Cancer: a Case Report | PDF",1790081066,15]